Optimizing CAR T cell therapy in lymphoma Conference Paper
| Authors: | Qualls, D.; Salles, G. |
| Title: | Optimizing CAR T cell therapy in lymphoma |
| Conference Title: | 16th International Conference on Malignant Lymphoma (ICML 2021) |
| Abstract: | Chimeric antigen receptor (CAR) T cell therapy has significantly improved the outlook for patients with certain types of poor-risk lymphoma. Despite these advances, a majority of patients undergoing CAR T therapy will suffer progression or relapse of disease, and toxicity remains a concern. Additionally, the patients and disease subtypes that are most likely to benefit from CAR T have yet to be fully defined. Many ongoing trials are exploring novel CAR T approaches to address these concerns. In this review, we highlight some of the primary strategies and relevant studies aimed at improving the utility of CAR T therapy in lymphoma. © 2021 John Wiley & Sons Ltd. |
| Keywords: | lymphoma; drug therapy; adoptive immunotherapy; immunotherapy, adoptive; cellular therapy; humans; human; receptors, chimeric antigen; chimeric antigen receptor t cell |
| Journal Title | Hematological Oncology |
| Volume: | 39 |
| Issue: | Suppl. 1 |
| Conference Dates: | 2021 Jun 18-22 |
| Conference Location: | Virtual |
| ISBN: | 0278-0232 |
| Publisher: | Wiley Blackwell |
| Date Published: | 2021-06-01 |
| Start Page: | 104 |
| End Page: | 112 |
| Language: | English |
| DOI: | 10.1002/hon.2844 |
| PUBMED: | 34105817 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- Export Date: 1 July 2021 -- Source: Scopus |
Altmetric
Citation Impact
Related MSK Work